Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q4 Preview: Looking For A Legacy Rebound
Tweet Send to a Friend
Canaccord Genuity maintains a 'Buy' on Valeant Pharmaceuticals (NYSE: VRX), PT $46.
Canaccord analyst says, "Valeant will report Q4/10 financial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Valeant will report Q4/10 financial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
